RED BLOOD CELL PROTECTIVE AGENT
|Posted date||Nov 2, 2018|
|International application number||2018JP005391|
|International publication number||WO 2018151243|
|Date of international filing||Feb 16, 2018|
|Date of international publication||Aug 23, 2018|
|Title||RED BLOOD CELL PROTECTIVE AGENT|
|Abstract||Provided is a red blood cell protective agent that allows for longer-term storage and safer use of a red blood cell-containing solution (e.g., red blood cell concentrate). When red blood cells are stored for a long period of time, phosphatidylserine (PS) is expressed on the surface of the red blood cell membranes. This red blood cell protective agent contains a histidine-rich glycoprotein (HRG) as an active component. HRG suppresses PS expression on red blood cell surfaces, and allows for longer-term storage and safer use of a red blood cell-containing solution.|
|Outline of related art and contending technology||
A blood product transfusion preparation red blood cells, plasma product, formulation and the whole blood platelet product and the like. Formulations are red blood cells, blood plasma, blood cells and platelets and remove the majority of the present invention. (Red blood cell: RBC) is the red blood cells, red blood cells and stored for a long time break down a dielectric film, release of hemoglobin, so-called hemolysis occurs. Is the blood concentrate, acid-sodium citrate-dextrose (Acid-citrate-dextrose) ACD solution including citric acid sodium-sodium phosphate-dextrose (Citrate-phosphate-dextrose) including CPD solution has been used more in the past. Further de-to compensate for the loss by reaction with the adenine, in recent years are adenine is added to the storage solution. 2-3 ° C. is the storage temperature after the valid period is 3 weeks and the blood, can be extended for up to 6 conditions is called. Continuously refrigerated storage of red blood cells however, a reduction in the consumption of glucose, metabolic wastes (i.e., lactic acid and a hydrogen ion) was confirmed to increase. Such a reduction in the metabolism of glucose, adenosine triphosphate (ATP) is depleted, causing a degradation of the red blood cells. After separating the cells from whole blood, red blood cells have been developed for storing. For example, (trade name) (AS-1) Adsol, (trade name) (AS-3) Nutricel, (trade name) (AS-5) Optosol Erythro-sol (trade name) and the like. These AS (AS-1, and the AS-3 AS-2) is, saline, adenine, glucose, as well as the 'protective agent of the cell membrane' a small amount of citric acid and/or as in the mannitol. Adenine and dextrose, at least one of the protective film 1 in an amount of sugar, blood pH buffer system for storage of the compositions and methods disclosed (Patent Document 1) is for.
Glycoprotein apoAII (Histidine-rich glycoprotein; HRG) is, in the year 1972 to about 80kDa molecular weight identified by Heimburger et al (1972) plasma protein. A total of 507 amino acids, wherein the histidine containing protein histidine and 66 high there, primarily synthesized in the liver, about 100-150μg/ml human is considered very high concentration present in the plasma. HRG is, the adjustment of the fibrinolytic system and coagulation line involved in the regulation of angiogenesis has been known (Non-Patent Document 1). Further, by administering the polypeptide HRG method of inhibiting angiogenesis, HRG polypeptide, a polypeptide an antibody that binds to the receptor and HRG, HRG-deficient plasma and polynucleotides, HRG vector encoding the polypeptide and host cells, the product and the pharmaceutical composition has been disclosed (Patent Document 2). In addition, relates to the field of angiogenesis, including HRG from the subfragments of the central region of the anti-angiogenic activity of the polypeptide is substantially pure of the continuous (Patent Document 3) there is a disclosure relating to the use. Further, the active ingredients of the neutrophils HRG-vascular endothelial cell adhesion inhibitor (Patent Document 4) is also described.
However, the safety of the red blood cells by HRG, the effect of stability will be, has not been reported. To protect the red blood cells has been desired the development of additional methods.
|Scope of claims||
|IPC(International Patent Classification)|
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Contact Information for " RED BLOOD CELL PROTECTIVE AGENT "
- Okayama University Intellectual Property Office
- URL: http://www.okayama-u.ac.jp/user/orpc-ehp/index/index.html
- Address: 1-1-1 Tsushima-naka , Kita-ku , Okayama-city, Japan , 700-8530
- Fax: 81-86-251-8961